Results 81 to 90 of about 10,308 (152)

Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance

Revista Brasileira de Hematologia e Hemoterapia, 2013
OBJECTIVE: The goal of this study was to monitor imatinib mesylate therapeutically in the Tumor Biology Laboratory, Department of Hematology and Hemotherapy, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (USP).
Vinícius Marcondes Rezende, Ariane Julio Rivellis, Melissa Medrano Gomes, Felipe Augusto Dörr, Mafalda Megumi Yoshinaga Novaes, Luciana Nardinelli, Ariel Lais de Lima Costa, Dalton de Alencar Fisher Chamone, Israel Bendit   +8 more
doaj  

Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters. [PDF]

Curr Ther Res Clin Exp, 2022
Omran MM, Shouman SA, Abdelfattah R, Moussa HS, Thabet NA, Hamza MS.   +5 more
europepmc   +1 more source

Imatinib Mesylate-Loaded Rosin/Cinnamon Oil-Based In Situ Forming Gel against Colorectal Cancer Cells. [PDF]

Gels, 2022
Khaing EM, Intaraphairot T, Mahadlek J, Okonogi S, Pichayakorn W, Phaechamud T.   +5 more
europepmc   +1 more source

Erratum: [Corrigendum] Imatinib mesylate and nilotinib decrease synthesis of bone matrix <i>in vitro</i>. [PDF]

Oncol Lett
Kroschwald LM, Tauer JT, Kroschwald SI, Suttorp M, Wiedenfeld A, Beissert S, Bauer A, Rauner M.   +7 more
europepmc   +1 more source

Imatinib Mesylate Reduces Neurotrophic Factors and pERK and pAKT Expression in Urinary Bladder of Female Mice With Cyclophosphamide-Induced Cystitis. [PDF]

Front Syst Neurosci, 2022
Perkins M, Girard BM, Campbell SE, Hennig GW, Vizzard MA.   +4 more
europepmc   +1 more source

Cannabidiol modulates exosomal miRNA networks to enhance Imatinib mesylate response in chronic myelogenous leukemia. [PDF]

Glob Med Genet
Donchev PP, Vasileva EY, Paunova-Krasteva TS, Danova ST.   +3 more
europepmc   +1 more source

Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD. [PDF]

Cell Transplant, 2022
Baek DW, Cho HJ, Kim JH, Ahn JS, Kim HJ, Lim SN, Cheong JW, Kim SY, Lee HS, Won JH, Yhim HY, Sohn SK, Moon JH.   +12 more
europepmc   +1 more source

Nail lichen planus associated with imatinib mesylate. [PDF]

JAAD Case Rep
Axler E, Loesch E, Vaidya T, Neubauer Z, Lipner SR.   +4 more
europepmc   +1 more source

Dynein axonemal heavy chain 9 M4374I variation may have an effect on imatinib mesylate resistance in CML. [PDF]

Med Int (Lond), 2022
Yildirim MS, Şi̇mşek L, Zamani̇ AG, Çeneli̇ Ö, Demi̇rci̇oğlu S.   +4 more
europepmc   +1 more source

Successful treatment of metastatic dermatofibrosarcoma protuberans of the breast to the lungs with imatinib mesylate: a case report. [PDF]

Ecancermedicalscience
Kpatsi S, Daniels J, Kyei KA, Vanderpuye V.   +3 more
europepmc   +1 more source